Cure8 research brief
The study pinpoints OTUD5 as a molecular driver of IFNγ-driven intestinal inflammation and links it to anti-TNFα nonresponse; blocking OTUD5 with a small molecule reduced colitis in mice and in human organoids, which could point to a future therapeutic strategy for patients who don't respond to existing biologics.
Researchers studying IBD immune mechanisms and drug discovery; clinicians and patients interested in causes of anti-TNFα treatment resistance; translational researchers working on small-molecule therapies for IBD.
The authors found OTUD5 was increased in colon biopsies from patients who did not respond to anti-TNFα treatment. In mice with OTUD5 removed specifically from intestinal epithelial cells, IFNγ-driven colitis was milder, with less weight loss and fewer inflammatory monocytes in the gut.
Mechanistically, OTUD5 appears to stabilize STAT1 and STAT2 proteins by preventing their ubiquitination and degradation, sustaining IFNγ–ISGF3 signaling and driving expression of CCL8, a chemokine that recruits monocytes.
A small-molecule inhibitor called CT1170 was reported to block OTUD5 activity, interrupt the IFNγ–ISGF3–CCL8 axis, reduce colitis progression in the mouse model, suppress colitis-associated tumor formation, and disrupt IFNγ signaling in patient-derived IBD organoids.
This is an abstract-level report of laboratory and preclinical work (mouse models and organoids). CT1170 is described here as an investigational small-molecule OTUD5 inhibitor; human safety, dosing, and efficacy data are not reported in this source.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study presents a mitochondria-targeted compound that reduced necrosis markers, HMGB1, and IL-1β in cell and mouse colitis models, highlighting a potential new pathway for IBD treatment research.
The study identifies a gut bacteria–liver signaling axis (Lactobacillus johnsonii → hepatic LXRα–SCD1) that may explain how altered hepatic lipids contribute to UC and related liver injury, and shows pristimerin can...
Intestinal fibrosis (stricture) is a serious, hard-to-treat complication of IBD/Crohn's disease. This preclinical study tests whether an antifibrotic drug used in lung fibrosis might reduce fibrosis in the gut, which...
